Related Experiment Video
Updated: Oct 8, 2025
13:53
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
5.1K
Glycan Microarrays Containing Synthetic Streptococcus pneumoniae CPS Fragments and Their Application to Vaccine
Paulina Kaplonek1,2, Peter H Seeberger3,4
1Department of Biomolecular Systems, Max-Planck-Institute of Colloids and Interfaces, Potsdam, Germany.
Methods in Molecular Biology (Clifton, N.J.)
|January 1, 2022
Summary
Developing new vaccines against Streptococcus pneumoniae, a major cause of childhood illness, is crucial. This study explores a medicinal chemistry approach using synthetic glycans for more efficient vaccine development.
Area of Science:
- Microbiology
- Immunology
- Medicinal Chemistry
Background:
- Streptococcus pneumoniae causes severe diseases like pneumonia, septicemia, and meningitis, particularly in young children.
- Over 98 serotypes of S. pneumoniae exist, differentiated by capsular polysaccharides (CPS).
- Current vaccines rely on CPS, but their isolation and processing are complex and labor-intensive.
Purpose of the Study:
- To present a medicinal chemistry strategy for developing glycoconjugate vaccines against S. pneumoniae.
- To highlight the use of synthetic glycans as an alternative to traditional CPS isolation.
- To introduce glycan arrays as a platform for identifying protective glycotopes.
Main Methods:
- Utilizing a medicinal chemistry approach for synthetic glycan antigen creation.
- Employing glycan arrays for high-throughput screening of serum samples.
- Identifying protective glycotopes for vaccine candidate development.
Main Results:
- Demonstrated the feasibility of using synthetic glycans for vaccine development.
- Showcased glycan arrays as an effective tool for identifying key antigenic determinants.
- Paved the way for a broader range of vaccine candidates targeting diverse S. pneumoniae serotypes.
Conclusions:
- Medicinal chemistry offers a promising alternative to conventional methods for pneumococcal vaccine development.
- Synthetic glycans and glycan arrays facilitate efficient identification of protective epitopes.
- This approach can accelerate the development of next-generation pneumococcal vaccines.
